Tekmira Establishes Regulatory Framework for Emergency Use of TKM-Ebola

VANCOUVER, British Columbia, Sept. 22, 2014 -- Tekmira Pharmaceuticals Corporation (TKMR) (TKM.TO), a leading developer of RNA interference (RNAi) therapeutics, today announced that the FDA has authorized Tekmira to provide TKM-Ebola for treatment under expanded access protocols to subjects with confirmed or suspected Ebola virus infections.

"Tekmira is reporting that an appropriate regulatory and clinical framework is now in place to allow the use of TKM-Ebola in patients. We have worked with the FDA and Health Canada to establish this framework and a treatment protocol allowing us to do what we can to help these patients," said Dr. Mark J. Murray Tekmira's President and CEO.

Published: 22 September 2014
Written by Editor
TSX   Nasdaq   FDA HC Decision  
Read more: Tekmira Pharmaceuticals Corporation ( TKM / TKMR )

Biostar Pharmaceuticals, Inc. Files a PRC Patent Application for Oleanolic Acid Injection, its New Drug Product for Hepatitis B and Liver Cancer

XIANYANG, China, Sept. 18, 2014  -- Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar" or the "Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today it has filed PRC national invention and creation patent for the pharmaceutical and preparation method of its new developed product, Oleanolic Acid Injection, which designed to treat Hepatitis B and liver cancer. The application passed the preliminary examination of the PRC State Intellectual Property Bureau and was accepted for review; the application acceptance number is 201410182757.7.

Published: 18 September 2014
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Biostar Pharmaceuticals Inc ( BSPM )

VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity

MOUNTAIN VIEW, CA and CHESTERBROOK, PA--- September 18, 2014) -  VIVUS, Inc. (VVUS) and Auxilium Pharmaceuticals, Inc. (AUXL) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA® (avanafil). STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.

Published: 18 September 2014
Written by Editor
Nasdaq   FDA HC Decision   Up on News  
Read more: VIVUS Inc ( VVUS )

ProQR Announces Pricing of Initial Public Offering

LEIDEN, Netherlands, Sept. 18, 2014  -- ProQR Therapeutics today announced the pricing of its initial public offering of 7,500,000 ordinary shares at an initial public offering price of $13.00 per ordinary share. In addition, ProQR has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 ordinary shares from ProQR at the public offering price, less underwriting discounts and commissions. After deducting the underwriting discounts and commissions and other estimated offering expenses payable by ProQR, the net proceeds of the initial public offering are expected to be approximately $88.4 million. The offering is expected to close on or about September 23, 2014, subject to customary closing conditions. ProQR's ordinary shares have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the symbol "PRQR" on September 18, 2014.

Published: 18 September 2014
Written by Editor
Nasdaq   Up on News   New Listing  
Read more: ProQR Therapeutics ( PRQR )

Foamix Pharmaceuticals Ltd. Prices Initial Public Offering

REHOVOT, Israel, and BRIDGEWATER, N.J., Sept. 18, 2014 -- Foamix Pharmaceuticals Ltd. ("Foamix Pharmaceuticals", or "Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, with its lead product minocycline foam for the treatment of acne, impetigo and other skin conditions, today announced the pricing of its initial public offering of 6.7 million ordinary shares at a price to the public of $6.00 per share. All of the ordinary shares are being offered by Foamix Pharmaceuticals. In addition, Foamix has granted the underwriters a 30-day option to purchase up to 1,005,000 additional ordinary shares. The shares are expected to begin trading on the NASDAQ Global Market on Thursday, September 18, 2014, under the ticker symbol "FOMX." The offering is expected to close on Tuesday, September 23, 2014, subject to customary closing conditions.

Published: 18 September 2014
Written by Editor
Nasdaq   Up on News   New Listing  
Read more: Foamix Pharmaceuticals Ltd ( FOMX )
  1. Soligenix Inc ( SNGX )
  2. Tokai Pharmaceuticals ( TKAI )
  3. CTI BioPharma Corp ( CTIC )
  4. Auxilium Pharmaceuticals Inc ( AUXL )
  5. Avanir Pharmaceuticals Inc ( AVNR )